Seqens opens collaborative R&D space after an ‘epiphany’

By Maggie Lynch contact

- Last updated on GMT

Seqens opens collaborative R&D space after an ‘epiphany’

Related tags: R&D, France, Collaboration, Clinical research, Pci pharma services

Seqens opens new center of excellence that houses R&D capabilities, onsite consulting, and space for coworking and collaboration in Porcheville, France.
seqens lab
Seqens lab

Seqens opened a 366,00sq-ft facility in Porcheville, France to serve as the company’s center of excellence. The facility, in close proximity to Paris, will provide R&D services to clinical research in the area and customers of Seqens North America, formerly known as PCI Synthesis.

The Procheville facility will be known as Seqens’Lab will offer expanded capabilities and include a coworking space for collaborative research.  

Christophe Eychenne-Baron, group R&D director at Seqens in Paris, told us that the company wanted to bring a new approach to finding ways to accelerate internal and customer projects that gathered its commercial team, R&D direction, and project management in one place.

According to the company, it is not just a shared laboratory and R&D hub but a ‘development accelerator.’

Eychenne-Baron explained, “We came to the epiphany that we could achieve our goals by gathering into one working area all the key internal function needed to deliver on-time projects.”

He added, “We intend to learn from our new practice here and look to roll out lessons learned and best practices to the rest of Seqens’ facilities around the world.”

Seqens’Lab will provide services in its ‘recognized areas of excellence’, including: organic chemistry development, reference to two laboratories in physics and solid-state chemistry and process safety, kinetic and thermodynamic simulation tools, and large batch manufacturing capabilities for preclinical and clinical studies.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars